Ferrolek solution for injections ampoules 50 mg/ml. 2 ml. №5

Description

FERROLEK FOR INJECTIONS COMPOSITION
active substance: 1 ml of iron dextran in terms of iron (iii) 50 mg

excipients: water for injection.

FERROLEK FOR INJECTIONS DOSAGE FORM
Injection.

FERROLEK FOR INJECTIONS MAIN PHYSICAL AND CHEMICAL PROPERTIES:
red-brown viscous liquid.

PHARMACOLOGICAL GROUP
Antianemic agents. Ferric iron preparations for parenteral administration. ATX code B0ZA C.

PHARMACOLOGICAL PROPERTIES
Pharmacological. Iron is an important constituent of hemoglobin, myoglobin, and several other enzymes. Its main role is the transfer of electrons, oxygen molecules and oxidative metabolism during tissue growth and proliferation. As an integral part of enzymes, iron is a catalyst for oxidation, hydroxylation and other vital metabolic processes.

Iron deficiency is formed with insufficient intake of iron from food, impaired absorption in the digestive tract, as well as with an increased need for it (increased growth, pregnancy) and, as a result, blood loss.

In the blood plasma, iron is carried by beta-globulin transferrin, which is synthesized in the liver. Each transferrin molecule binds to two iron atoms. In combination with transferrin, iron is transported to the cells of the body, where it reversibly binds to ferritin and is used to synthesize hemoglobin, myoglobin and some enzymes.

After parenteral administration of iron dextran, the level of hemoglobin rises faster than after the administration of iron salts inside, despite the absence of dependence of the kinetics of iron incorporation on the route of its administration.

The size of the iron dextran complex is large enough, so its excretion by the kidneys is impossible. This complex is stable and there is no release of iron in the form of ions under physiological conditions.

The macromolecular dextran complex enters the reticuloendothelial system, where it breaks down into an iron component and dextran. Iron then binds to ferritin or hemosiderin and, to a lesser extent, to transferin and is used to synthesize hemoglobin. Dextran is metabolized or excreted. The amount of iron removed is negligible.

INDICATIONS
Treatment of iron deficiency states with ineffectiveness or impossibility of treatment with iron preparations for oral administration.

CONTRAINDICATIONS
Hypersensitivity to the components of the drug, excess iron in the body (for example, hemochromatosis, hemosiderosis), impaired inclusion of iron in hemoglobin (for example, anemia caused by lead poisoning, sideroachrestic anemia, thalassemia), anemia, not due to iron deficiency (for example, hemolytic anemia, megaloblastic anemia ), severe hemostasis disorders (hemophilia), erythropoiesis disorders, bone marrow hypoplasia, cutaneous porphyria.

INTERACTION WITH OTHER DRUGS AND OTHER INTERACTIONS
The effectiveness of parenteral iron preparations increases with their simultaneous use with ACE inhibitors.

The drug should not be administered concomitantly with oral iron preparations. Treatment with oral iron preparations should be started at least 5 days after the last injection of iron preparation.